Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 24 peer-reviewed journal articles Updated
Hematology · Chronic Myeloid Leukemia

How Do Doctors Distinguish Ph+ CML From Ph+ ALL and MPNs?

At a Glance

The Philadelphia chromosome alone cannot confirm CML. Doctors combine the number and maturity of blood cells, bone marrow findings, cell-marker tests, genetic results, and medical history to distinguish CML from Ph+ ALL and other disorders.

In this answer

4 sections

01

The Testing Toolkit

02

Distinguishing Ph+ CML from Ph+ ALL

03

Differentiating CML from Ph-Negative MPNs

04

Ruling Out Leukemoid Reactions

Finding the Philadelphia chromosome—a structural change where two chromosomes swap pieces—creates the BCR::ABL1 fusion gene. Detecting this fusion is essential for diagnosing Philadelphia chromosome-positive (Ph+) Chronic Myeloid Leukemia (CML) [1]. However, this finding alone is not enough to confirm CML, because the BCR::ABL1 fusion can also drive other blood cancers, most notably Philadelphia-positive Acute Lymphoblastic Leukemia (Ph+ ALL) [1].

Because the treatments and outlooks for these conditions are different, doctors use a combination of blood counts, bone marrow examination, specialized genetic tests, and your clinical history to build a complete picture and rule out other possibilities.

The Testing Toolkit

Doctors use several specialized tests to distinguish between these overlapping conditions:

Test What it Evaluates How it Helps
Complete Blood Count (CBC) & Smear The number and appearance of cells in your blood. Identifies if you have an excess of mature white cells (favoring CML) or immature blasts (favoring ALL) [2].
Bone Marrow Aspirate & Biopsy The structure, cell types, and blast percentage in the marrow. Shows if the marrow has characteristic CML features or is packed with lymphoblasts [3].
Flow Cytometry Specific proteins on the surface of blood or marrow cells. Identifies the lineage of cells (e.g., myeloid vs. lymphoid) to help categorize the disease [4].
Karyotype & FISH The physical structure of your chromosomes inside the cells. Visually confirms the Philadelphia chromosome or complex structural changes [5].
RT-PCR The exact genetic sequence and amount of the BCR::ABL1 fusion. Determines which specific transcript (like e13a2 or e1a2) your cells are producing [6].

Distinguishing Ph+ CML from Ph+ ALL

While both conditions involve the BCR::ABL1 fusion gene, CML typically starts as a slow-growing overproduction of maturing cells, while Ph+ ALL is an acute, fast-growing leukemia of immature cells.

Blast Percentages and Cell Types

In a healthy person, immature blood cells called blasts make up a very small fraction of bone marrow cells and are rarely seen in the blood [7].

  • CML (Chronic Phase): CML typically presents with fewer than 10% blasts in the blood and bone marrow [7]. The blood shows an overproduction of maturing white blood cells (granulocytes) at all stages of development, and often includes elevated basophils (a specific white blood cell) and an enlarged spleen [2][8].
  • Ph+ ALL and Blast Phase CML: A diagnosis of acute leukemia, or CML in “blast phase,” generally requires 20% or more blasts in the blood or marrow [7][9]. (If blasts are between 10% and 19%, some classification systems call this an “accelerated phase” [10]).

The Challenge of Blast Phase

When CML progresses to a “lymphoid blast phase,” the bone marrow fills with lymphoblasts, and the disease can look nearly identical to newly occurring (de novo) Ph+ ALL [10][9]. Doctors use several clues to tell them apart:

  • Transcript Types: The exact point where the genes fuse can vary. Transcripts like e13a2 or e14a2 produce a fusion protein called p210, which is the hallmark of CML [11]. The e1a2 transcript produces the p190 protein, which is most common in Ph+ ALL [11][12]. However, this is only a probability clue, not an absolute rule: CML blast phase can sometimes have p190, and Ph+ ALL can have p210 [9][13].
  • Multilineage Involvement: If specialized testing detects the BCR::ABL1 fusion inside mature segmented neutrophils as well as the blasts, it strongly supports a CML origin [14][1]. However, this specialized testing is not always available, and a lack of fusion in mature cells does not entirely rule out CML.
  • Flow Cytometry: This test establishes cell lineage and maturation stage. While blasts in both diseases can show B-lymphoid markers, CML blast-phase cells may retain certain myeloid markers [15][16]. Because mixed markers can occur in both, flow cytometry must be interpreted alongside your medical history (such as prior CBC results showing a chronic phase) and other tests.

Differentiating CML from Ph-Negative MPNs

Myeloproliferative Neoplasms (MPNs) are disorders where the bone marrow overproduces blood cells. CML is one type, but there are others, including Polycythemia Vera (PV), Essential Thrombocythemia (ET), and Primary Myelofibrosis (PMF) [17].

Because CML can sometimes cause high platelet counts mimicking ET, doctors must distinguish them [18].

  • Genetic Markers: PV, ET, and PMF are classified as BCR::ABL1-negative [19]. Instead, they are typically driven by different mutations in the JAK2, CALR, or MPL genes [19][20]. If CML is ruled out, your doctor may check for these mutations.
  • Bone Marrow Morphology: Under a microscope, PV usually shows panmyelosis (overgrowth of multiple cell types), ET shows large, mature megakaryocytes with hyperlobulated nuclei, and PMF often shows scar tissue (fibrosis) in the marrow [3]. In contrast, CML marrow typically features distinct, small, hypolobated megakaryocytes [8].

Ruling Out Leukemoid Reactions

A leukemoid reaction is a massive, temporary spike in white blood cells reacting to severe infection, intense physical stress, or inflammation [21]. Because it causes a high white count, it can be mistaken for CML.

A leukemoid reaction is not a cancer and will typically test negative for the BCR::ABL1 fusion [22]. Additionally, a blood smear from a leukemoid reaction will usually show mostly mature neutrophils with “toxic granulation” (dark spots reacting to infection), and it generally lacks the elevated basophils characteristic of CML [8][23].

(Note: In rare cases, a patient might have a different BCR::ABL1-positive leukemia, such as mixed-phenotype acute leukemia, or a rare Ph-negative disorder like Chronic Neutrophilic Leukemia [24]. Your hematopathologist evaluates the entire picture to ensure the correct diagnosis. Patients should never interpret a high white count or a single transcript type on its own.)

Common questions in this guide

Can the Philadelphia chromosome by itself diagnose CML?
No. The BCR::ABL1 fusion can also occur in Ph+ ALL and other uncommon blood cancers. Doctors therefore combine blood counts, bone marrow findings, flow cytometry, chromosome studies, molecular tests, and clinical history.
What blast count helps separate chronic-phase CML from acute leukemia?
Chronic-phase CML usually has fewer than 10% blasts in the blood and bone marrow. Acute leukemia or CML in blast phase generally has 20% or more blasts, while 10% to 19% may be classified as an accelerated phase under some systems. Doctors also assess which cells are present and whether they are maturing normally.
Can the BCR::ABL1 transcript identify whether I have CML or Ph+ ALL?
An e13a2 or e14a2 transcript that produces p210 is more typical of CML, while e1a2 producing p190 is more common in Ph+ ALL. These patterns are clues, not proof, because blast-phase CML can have p190 and Ph+ ALL can have p210. The result must be interpreted with the other test findings.
How do flow cytometry and bone marrow testing help distinguish CML from Ph+ ALL?
Flow cytometry shows whether abnormal cells are B-lymphoid, myeloid, or another lineage and how mature they are. Bone marrow examination shows the proportion and appearance of blasts; chronic-phase CML usually has maturing granulocytes, whereas Ph+ ALL is dominated by lymphoblasts. CML blast phase can overlap with Ph+ ALL, so the full clinical history matters.
How is CML distinguished from other myeloproliferative neoplasms?
Polycythemia vera, essential thrombocythemia, and primary myelofibrosis are usually BCR::ABL1-negative and often have JAK2, CALR, or MPL mutations. Bone marrow appearance also helps: CML typically has small, hypolobated megakaryocytes, while the other disorders have characteristic patterns such as fibrosis or large, mature megakaryocytes. Doctors use both genetic and microscopic findings.
How can doctors tell CML from a leukemoid reaction?
A leukemoid reaction is a temporary, noncancerous rise in white blood cells caused by infection, inflammation, or major physical stress. It usually lacks the BCR::ABL1 fusion and often shows toxic granulation with fewer basophils than CML. Doctors interpret these findings alongside symptoms and medical history.

Related questions

What Happens If CML Misses 3-, 6-, or 12-Month Milestones? What Lifestyle Advice Applies During CML TKI Treatment? What Does an Undetectable BCR::ABL1 PCR Result Mean? What Are the WHO, ICC, and ELN CML Phase Definitions? What Drug and Food Interactions Affect CML TKI Treatment?
Show more
How Often Are CML PCR and CBC Tests Done After a TKI? How Do BCR::ABL1 Transcripts Affect CML Monitoring? How Does CML Progress from Chronic to Blast Phase? How Common Is Ph+ CML and What Age Is It Diagnosed? How Is Ph-Positive CML Different From Other Blood Cancers? What Does the ELTS Risk Score Mean in Ph+ CML Patients? What Is Life Expectancy for Adults With Ph+ CML Today? What Tests Confirm Philadelphia-Positive CML and Its Phase? How Do Health Conditions Affect First-Line CML TKI Choice? Why Do My CML PCR Results Change When I Feel Fine? Can Ph-Positive CML Cause Leukostasis Without Symptoms? How Is a Rising BCR::ABL1 in CML Checked for TKI Resistance? What Does 10% to 19% Blasts Mean for Ph+ CML Patients? What Should I Do About a Rising BCR::ABL1 PCR in CML?

Get notified when new evidence is published on Philadelphia-positive myelogenous leukemia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (24)
  1. 1

    Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Is Separated into Two Subgroups Associated with Survival by BCR-ABL Fluorescence in situ Hybridization of Segmented Cell Nuclei: Report from a Single Institution.

    Kamoda Y, Izumi K, Iioka F, et al.

    Acta haematologica 2016; (136(3)):157-66 doi:10.1159/000445972.

    PMID: 27537935
  2. 2

    A Case Report of Chronic Myelogenous Leukemia Presenting as Blastic Crisis with a T-Cell Acute Lymphoblastic Leukemia Phenotype: Awareness of a Rare Entity.

    Efstathopoulou M, Zoi K, Siakantaris MP, et al.

    Acta haematologica 2023; (146(6)):531-539 doi:10.1159/000529911.

    PMID: 37557081
  3. 3

    The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion.

    Barbui T, Thiele J, Gisslinger H, et al.

    Blood cancer journal 2018; (8(2)):15 doi:10.1038/s41408-018-0054-y.

    PMID: 29426921
  4. 4

    An Unusual Presentation of Philadelphia Chromosome Positive B-Cell Acute Lymphoblastic Leukemia With Isolated Osteolytic Lesions at Diagnosis: A Case Report.

    Zhang T, Jamy O, Rangaraju S

    Case reports in hematology 2026; (2026()):2728902 doi:10.1155/crh/2728902.

    PMID: 42472062
  5. 5

    FISH-negative BCR::ABL1-positive e19a2 chronic myeloid leukaemia: the most cryptic of insertions.

    May PC, Reid AG, Robinson ME, et al.

    BMC medical genomics 2023; (16(1)):172 doi:10.1186/s12920-023-01607-7.

    PMID: 37496024
  6. 6

    Assessment of individual molecular response in chronic myeloid leukemia patients with atypical BCR-ABL1 fusion transcripts: recommendations by the EUTOS cooperative network.

    Schäfer V, White HE, Gerrard G, et al.

    Journal of cancer research and clinical oncology 2021; (147(10)):3081-3089 doi:10.1007/s00432-021-03569-8.

    PMID: 33677711
  7. 7

    Chronic Myeloid Leukemia: A Review.

    Jabbour E, Kantarjian H

    JAMA 2025; (333(18)):1618-1629 doi:10.1001/jama.2025.0220.

    PMID: 40094679
  8. 8

    Preleukemic phase of chronic myelogenous leukemia: morphologic and immunohistochemical characterization of 7 cases.

    Aye le L, Loghavi S, Young KH, et al.

    Annals of diagnostic pathology 2016; (21()):53-8.

    PMID: 27040932
  9. 9

    Chronic myeloid leukemia presenting in lymphoblastic crisis, a differential diagnosis with Philadelphia-positive B-lymphoblastic leukemia.

    Chen Z, Hu S, Wang SA, et al.

    Leukemia & lymphoma 2020; (61(12)):2831-2838 doi:10.1080/10428194.2020.1795160.

    PMID: 32700989
  10. 10

    Advanced-Stage Chronic Myeloid Leukemia: Options for Difficult Treatment Situations.

    Atallah E, Deininger M

    Drugs 2025; (85(1)):41-50 doi:10.1007/s40265-024-02108-2.

    PMID: 39638957
  11. 11

    BCR::ABL1 e1a2 (p190)-Positive Myeloid Blast Neoplasm: Diagnostic Challenges in Distinguishing De Novo Acute Myeloid Leukemia From Previously Unrecognized Chronic Myeloid Leukemia in the Blast Phase.

    González Quiroz V, Campillo González RS, Garay Hernandez JA, et al.

    Cureus 2026; (18(7)):e113606 doi:10.7759/cureus.113606.

    PMID: 42667018
  12. 12

    Current paradigms in the management of Philadelphia chromosome positive acute lymphoblastic leukemia in adults.

    El Fakih R, Jabbour E, Ravandi F, et al.

    American journal of hematology 2018; (93(2)):286-295 doi:10.1002/ajh.24926.

    PMID: 28971501
  13. 13

    Outcome of patients with chronic myeloid leukemia in lymphoid blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia treated with hyper-CVAD and dasatinib.

    Morita K, Kantarjian HM, Sasaki K, et al.

    Cancer 2021; (127(15)):2641-2647 doi:10.1002/cncr.33539.

    PMID: 33823073
  14. 14

    Blast phase of chronic myeloid leukemia presenting as early T-cell precursor acute lymphoblastic leukemia.

    E S, Xu J, Wang SA, et al.

    American journal of clinical pathology 2025; (163(2)):231-239 doi:10.1093/ajcp/aqae115.

    PMID: 39235991
  15. 15

    B-Lymphoid Blast Phase of Chronic Myeloid Leukemia: A Case Report and Review of the Literature.

    Ware AD, Wake L, Brown P, et al.

    AJSP: reviews & reports 2019; (24(5)):191-195.

    PMID: 32656356
  16. 16

    De novo lymphoid blastic phase chronic myeloid leukemia: report and contemporary discussion.

    Hameed M, Alnoamani M, Marei M, et al.

    Hematology (Amsterdam, Netherlands) 2022; (27(1)):1259-1262 doi:10.1080/16078454.2022.2150386.

    PMID: 36448578
  17. 17

    Cytological Diagnosis of Classic Myeloproliferative Neoplasms at the Age of Molecular Biology.

    Combaluzier S, Quessada J, Abbou N, et al.

    Cells 2023; (12(6)) doi:10.3390/cells12060946.

    PMID: 36980287
  18. 18

    Thrombocytosis and STAT5 activation in chronic myelogenous leukaemia are not associated with JAK2 V617F or calreticulin mutations.

    Turakhia SK, Murugesan G, Cotta CV, Theil KS

    Journal of clinical pathology 2016; (69(8)):713-9 doi:10.1136/jclinpath-2015-203498.

    PMID: 26754830
  19. 19

    Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms.

    Rumi E, Cazzola M

    Blood 2017; (129(6)):680-692 doi:10.1182/blood-2016-10-695957.

    PMID: 28028026
  20. 20

    Genetic basis and molecular profiling in myeloproliferative neoplasms.

    Luque Paz D, Kralovics R, Skoda RC

    Blood 2023; (141(16)):1909-1921 doi:10.1182/blood.2022017578.

    PMID: 36347013
  21. 21

    Leukemoid reaction: A 21st-century cohort study.

    Portich JP, Faulhaber GAM

    International journal of laboratory hematology 2020; (42(2)):134-139 doi:10.1111/ijlh.13127.

    PMID: 31765058
  22. 22

    Diagnosis, complications and management of chronic neutrophilic leukaemia: A case report.

    Silva PR, Ferreira C, Bizarro S, et al.

    Oncology letters 2015; (9(6)):2657-2660 doi:10.3892/ol.2015.3148.

    PMID: 26137123
  23. 23

    Colonic pleomorphic undifferentiated sarcoma with a leukemoid reaction: case report.

    Wang R, Shan T, Mu D, et al.

    Frontiers in medicine 2026; (13()):1883302 doi:10.3389/fmed.2026.1883302.

    PMID: 42460083
  24. 24

    The spectrum of Ph-negative disease: CNL and CSF3R-related disorders.

    Hasserjian RP

    Hematology. American Society of Hematology. Education Program 2024; (2024(1)):270-278 doi:10.1182/hematology.2024000555.

    PMID: 39643989

This page is for informational purposes only and does not constitute medical advice. A hematologist or hematopathologist must interpret your complete blood, marrow, flow cytometry, chromosome, and BCR::ABL1 results.